Literature DB >> 29950497

Possible SAMe-induced mania.

Hesitha Abeysundera1, Ramandeep Gill2.   

Abstract

This paper describes a patient who presented with mania with psychotic features in the context of concomitant use of S-adenosyl-L-methionine (SAMe) and selective serotonin reuptake inhibitor (SSRI). The aim of this case report is to provide medical practitioners with a greater awareness of the possibility of a psychotic episode and/or mania manifesting with concurrent use of SAMe and SSRI. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  bipolar I disorder; depressive disorder; drugs: psychiatry; psychiatry (drugs and medicines); psychotic disorders (incl schizophrenia)

Mesh：

Substances：

Year:  2018        PMID： 29950497      PMCID： PMC6040551          DOI： 10.1136/bcr-2018-224338

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  16 in total

1.  S-Adenosylmethionine; a new intermediate formed enzymatically from L-methionine and adenosinetriphosphate.

Authors:  G L Cantoni
Journal:  J Biol Chem       Date:  1953-09       Impact factor: 5.157

Review 2.  Folates and psychiatric disorders. Clinical potential.

Authors:  R Crellin; T Bottiglieri; E H Reynolds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

3.  A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis.

Authors:  B König
Journal:  Am J Med       Date:  1987-11-20       Impact factor: 4.965

4.  Effect of s-adenosyl-l-methionine (SAMe) upon depressive symptoms.

Authors:  A Agnoli; V Andreoli; M Casacchia; R Cerbo
Journal:  J Psychiatr Res       Date:  1976       Impact factor: 4.791

5.  The switch mechanism and the bipolar/unipolar dichotomy.

Authors:  M W Carney; T K Chary; T Bottiglieri; E H Reynolds
Journal:  Br J Psychiatry       Date:  1989-01       Impact factor: 9.319

6.  Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans.

Authors:  Jessica L Gören; Andrew L Stoll; Karen E Damico; Ingrid A Sarmiento; Bruce M Cohen
Journal:  Pharmacotherapy       Date:  2004-11       Impact factor: 4.705

7.  S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine.

Authors:  Jonathan E Alpert; George Papakostas; David Mischoulon; John J Worthington; Timothy Petersen; Yasmin Mahal; Alana Burns; Teodoro Bottiglieri; Andrew A Nierenberg; Maurizio Fava
Journal:  J Clin Psychopharmacol       Date:  2004-12       Impact factor: 3.153

8.  Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation.

Authors:  S Jacobsen; B Danneskiold-Samsøe; R B Andersen
Journal:  Scand J Rheumatol       Date:  1991       Impact factor: 3.641

9.  S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies.

Authors:  G M Bressa
Journal:  Acta Neurol Scand Suppl       Date:  1994

Review 10.  S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism.

Authors:  H A Friedel; K L Goa; P Benfield
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546
View more
  1 in total

Review 1.  The Efficacy of S-Adenosyl Methionine and Probiotic Supplementation on Depression: A Synergistic Approach.

Authors:  Hammad Ullah; Ayesha Khan; Kannan R R Rengasamy; Alessandro Di Minno; Roberto Sacchi; Maria Daglia
Journal:  Nutrients       Date:  2022-07-01       Impact factor: 6.706
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.